Patents Assigned to Galderma Research & Development
  • Patent number: 11731973
    Abstract: The invention relates to novel mTOR inhibitor compounds having the formula (I) or a pharmaceutically acceptable salt thereof, compositions comprising the mTOR inhibitor compounds, methods for producing the same, and the use thereof.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: August 22, 2023
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Laurence Clary, Jean-François Fournier, Gilles Ouvry, Yushma Bhurruth-Alcor, Etienne Thoreau, Loïc Tomas
  • Patent number: 11730814
    Abstract: The present invention is related to a pulse photodynamic therapy (or pulse PDT) treatment of photodamaged skin.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: August 22, 2023
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Hans Christian Wulf, Gloria Sanclemente
  • Patent number: 11518767
    Abstract: The invention relates to novel mTOR inhibitor compounds having the general formula (I), to compositions comprising said mTOR inhibitor compounds, methods for producing same, and the use thereof in compositions as a drug.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: December 6, 2022
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Laurence Clary, Jean-François Fournier, Gilles Ouvry, Yushma Bhurruth-Alcor, Etienne Thoreau, Loïc Tomas
  • Publication number: 20220081519
    Abstract: A new hydrogel made of crosslinked glycosaminoglycans, particularly crosslinked hyaluronic acid, chondroitin or chondroitin sulfate, having reversible linkages using boronic acid or boroxole derivatives leading to new benefits. Glycosaminoglycans that are crosslinked via an alkoxyboronate ester anion formed between a diol portion of a diol-functional moiety grafted to a first glycosaminoglycan and a boronate hemiester grafted to a second glycosaminoglycan.
    Type: Application
    Filed: November 24, 2021
    Publication date: March 17, 2022
    Applicants: Galderma Research & Development, Centre National de la Recherche Scientifique
    Inventors: Rachel AUZELY-VELTY, Tamiris FIGUEIREDO, Laura JING JING, Craig Steven HARRIS, Jean-Guy BOITEAU, Thibaut GERFAUD, Loic TOMAS
  • Patent number: 11235010
    Abstract: A composition is described that includes at least one lactic acid bacteria, preferably Lactobacillus johnsonii LA1 NCC 533 (deposit number CNCM I-1225) in an acceptable carrier. Also described, is use of the composition in the treatment and/or prevention of a dermatological disease, preferably atopic dermatitis.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: February 1, 2022
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventor: Carine Rosignoli
  • Patent number: 11234931
    Abstract: A self-foaming composition is described that includes brimonidine, for a no-rinse topical application. The composition can include: at least one intermediate composition B including a gas-generating agent; at least one intermediate composition A including an agent for activating the gas-generating agent; and brimonidine or one of the pharmaceutically acceptable salts thereof being present in at least one of the intermediate compositions A and B. Also described, is a kit or a single container including a plurality of compartments including such a composition.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: February 1, 2022
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Jean-Christophe Buge, Karine Nadau-Fourcade
  • Patent number: 11214655
    Abstract: A new hydrogel made of crosslinked glycosaminoglycans, particularly crosslinked hyaluronic acid, chondroitin or chondroitin sulfate, having reversible linkages using boronic acid or boroxole derivatives leading to new benefits. Glycosaminoglycans that are crosslinked via an alkoxyboronate ester anion formed between a diol portion of a diol-functional moiety grafted to a first glycosaminoglycan and a boronate hemiester grafted to a second glycosaminoglycan.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: January 4, 2022
    Assignees: GALDERMA RESEARCH & DEVELOPMENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTFIQUE
    Inventors: Rachel Auzely-Velty, Tamiris Figueiredo, Laura Jing Jing, Craig Steven Harris, Jean-Guy Boiteau, Thibaut Gerfaud, Loic Tomas
  • Publication number: 20210404004
    Abstract: A method is described for using IL-12R?1/IL-23R, CCR6, BATF, AHR, STAT3, IRF4 crucial actors in TH17 cells differentiation as markers for acne. Also described are methods of their use to diagnose acne, and to screen inhibitors of Th17 differentiation. In particular, methods are described for inhibiting IL12R?1/1L-23R, CCR6, BATF, AHR, STAT3, IRF4 and the use of these screened inhibitors in acne treatment.
    Type: Application
    Filed: July 6, 2021
    Publication date: December 30, 2021
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventor: Isabelle Carlavan
  • Patent number: 11160812
    Abstract: A self-foaming composition is described that includes clobetasol propionate, for a no-rinse topical application and for application to the skin. The composition can include: at least one intermediate composition B including a gas-generating agent; at least one intermediate composition A including an agent for activating the gas-generating agent; and clobetasol propionate being present in at least one of the intermediate compositions A and B. Also described, is a kit or a single container including a plurality of compartments including such a composition.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: November 2, 2021
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Jean-Christophe Buge, Karine Nadau-Fourcade
  • Patent number: 11020347
    Abstract: A self-foaming composition is described that includes trifarotene, for a no-rinse topical application and for application to the skin. The composition can include: at least one intermediate composition B including a gas-generating agent; at least one intermediate composition A including an agent for activating the gas-generating agent; and trifarotene or one of the pharmaceutically acceptable salts thereof being present in at least one of the intermediate compositions A and B. The composition is particularly intended for the treatment of acne. Also described is a kit or a single container including a plurality of compartments including such a composition.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: June 1, 2021
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Jean-Christophe Buge, Karine Nadau-Fourcade
  • Patent number: 11020348
    Abstract: A self-foaming composition is described that includes trifarotene, for a no-rinse topical application. The composition can include: at least one intermediate composition B including a gas-generating agent; at least one intermediate composition A including an agent for activating the gas-generating agent; and trifarotene or one of the pharmaceutically acceptable salts thereof being present in at least one of the intermediate compositions A and B. The composition is particularly intended for the treatment of ichthyosis. Also described, is a kit or a single container including a plurality of compartments including such a composition.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: June 1, 2021
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Jean-Christophe Buge, Karine Nadau-Fourcade
  • Publication number: 20210138068
    Abstract: The present invention is related to a pulse photodynamic therapy (or pulse PDT) treatment of photodamaged skin.
    Type: Application
    Filed: December 15, 2020
    Publication date: May 13, 2021
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Hans Christian WULF, Gloria SANCLEMENTE
  • Patent number: 10995052
    Abstract: Compounds of general formula (I) are described. Also described, is the use of such compounds in pharmaceutical compositions for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmologic disorders, in particular), or in cosmetic compositions.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: May 4, 2021
    Assignee: Galderma Research & Development
    Inventor: Thibaud Portal
  • Patent number: 10987307
    Abstract: A self-foaming composition is described that includes ivermectin, for a no-rinse topical application and for application to the skin. The composition can include: at least one intermediate composition B including a gas-generating agent; at least one intermediate composition A including an agent for activating the gas-generating agent; and ivermectin being present in the composition A, in the composition B, or simultaneously in the two compositions A and B. Also described, is a kit or a single container including a plurality of compartments including such a composition.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: April 27, 2021
    Assignee: Galderma Research & Development
    Inventors: Jean-Christophe Buge, Karine Nadau-Fourcade
  • Publication number: 20210096120
    Abstract: The invention relates to a method for determining in vitro release rate of at least one active principle ingredient from at least one semisolid form.
    Type: Application
    Filed: September 11, 2020
    Publication date: April 1, 2021
    Applicant: Galderma Research & Development
    Inventors: Brzokewicz Alain, Hélène Huguet
  • Patent number: 10953094
    Abstract: The present invention is related to a pulse photodynamic therapy (or pulse PDT) treatment of photodamaged skin.
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: March 23, 2021
    Assignee: Galderma Research & Development
    Inventors: Hans Christian Wulf, Gloria Sanclemente
  • Patent number: 10925855
    Abstract: A composition or nanosuspension is described that includes water dispersible nanoparticles of a retinoid compound having an average particle size of less than about 500 nm. Also described, are pharmaceutical compositions intended for topical administration, including such a composition or nanosuspension. Uses of such pharmaceutical compositions in the treatment of skin diseases, particularly acne, ichthyosis and psoriasis are also described.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: February 23, 2021
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Claire Mallard, Amel Safia Djedour
  • Patent number: 10925814
    Abstract: Stable cream gel dermatological/cosmetic compositions useful, e.g., for the treatment of acne vulgaris, contain, formulated into a physiologically acceptable medium, a homogeneous dispersion of at least one dispersed retinoid, dispersed benzoyl peroxide, at least one lipophilic compound and at least one gelling agent.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: February 23, 2021
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Claire Mallard, Fabienne Louis, Emmanuelle At Guillet
  • Patent number: 10925822
    Abstract: A method is described for producing an oil-in-water emulsion including oil globules, the mean diameter of which is less than 500 nm and each of which is provided with a lamellar liquid crystal coating, and which are dispersed in an aqueous phase. Each oil globule is individually coated with a unilamellar or oligolamellar layer obtained from at least one lipophilic surfactant, at least one hydrophilic surfactant, and at least one separate anionic surfactant, characterized in that the number of steps in the method is no greater than 5, in that the temperatures used during the different steps are no higher than 75° C., and in that the method requires neither the use of a high-pressure homogenizer nor any pre-emulsification step.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: February 23, 2021
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventor: Amel Safia Djedour
  • Patent number: 10857123
    Abstract: The use of an NLRP3 inhibitor compound is described in the treatment of inflammatory skin disorders, in particular psoriasis and atopic dermatitis.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: December 8, 2020
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventor: Feriel Hacini-Rachinel